Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis
Item LinksURI: http://hdl.handle.net/10818/43203
Visitar enlace: https://pubmed.ncbi.nlm.nih.go ...
Visitar enlace: https://link.springer.com/arti ...
DOI: https://doi.org/10.1007/s10067 ...
StatisticsView Usage Statistics
Altmetric and Scopus Metrics
Bibliographic catalogingShow full item record
AuthorRomero Sánchez, Consuelo; Robinson, William H.; Tomooka, Beren H.; Londoño, John; Valle Oñate, Rafael; Huang, Feng; Deng, Xiaohu; Zhang, Liyun; Yang, Chunhua; Tak Yan Yu, David
Although most ankylosing spondylitis patients show an apparent clinical response to infliximab therapy, there is considerable individual variation. Because current clinical assessment relies heavily on subjective patient self-evaluation, biomarkers of high sensitivity and specificity are much needed. Here, we assessed potential biomarkers in 47 ankylosing spondylitis patients who received three standard pulses of infliximab. Before each infusion and at week 10, the following were measured: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), platelet count, serum levels of metalloproteinase-3 (MMP-3), and 22 different cytokines. We discovered that, 2 weeks after the first infusion, the combination of ESR, CRP, and platelet count distinguished responders from non-responders with 81.3% sensitivity and 72.7% specificity. The distinguishing power was much less when each acute phase reactant was used alone. Among the 22 cytokines, serum IL-1alpha was able to distinguish responders from non-responders at week 6, with sensitivity of 84.9% and specificity of 53.8%. Serum IL-1alpha was probably generated from the joint compartments, as synovial fluid levels were much higher than corresponding serum levels. Although infliximab infusions led to rapid and significant suppression of serum MMP-3 levels, serum MMP-3 levels did not distinguish responders from non-responders. Besides identifying potential biomarkers, our results also demonstrate the usefulness of using sensitivity and specificity to assess usefulness of potential biomarkers.
Clinical Rheumatology volume 27, pages1429–1435(2008)
Collections to which it belong
- Facultad de Medicina